Replies to post #90047 on Biotech Values

[DewDiligence]

AUXL’s 2Q10 sales of Xiaflex were $2.0M:

http://www.reuters.com/article/idUKSGE66B0FG20100712

Yes, this was the first full quarter of sales. Nevertheless, $2M is chump change; AUXL may have overstated the size of the addressable market for this drug.